HC Wainwright Has Positive Outlook of MNPR FY2027 EarningsMarket Beat·1 day ago, 06:27 AMMNPR+3.95%JPM+0.95%
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125Tip Ranks·Jul 22 at 10:15 AMMNPR+3.95%
Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson diseasePUBT·Jul 22 at 07:01 AMMNPR+3.95%
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRSrttnews·Jul 21 at 02:45 AMMNPR+3.95%SOPH-5.45%
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLTrttnews·Jul 10 at 07:21 AMTRAX-5.63%MPLT+3.78%
Monopar Therapeutics director Nicole Sweeny files initial beneficial ownership statementPUBT·Jun 30 at 03:58 PMMNPR+3.95%
Monopar says FDA grants rare pediatric disease designation for ALXN1840 in Wilson diseasePUBT·Jun 30 at 07:02 AMMNPR+3.95%
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease | MNPR Stock NewsStockTitan·Jun 26 at 07:05 AMMNPR+3.95%
